阿托伐他汀联合雄激素阻断对晚期前列腺癌术后患者血清PSA、VEGF、MMP-9及血脂水平的影响  

Effects of atorvastatin combined with androgen blockade on serum PSA,VEGF,MMP-9 and blood lipid levels in patients with advanced prostate cancer

作　　者：徐磊[1] 车宪平[1] 古军[1] 陈化磊[1] 胡鑫明[1] 周世英 Xu Lei;Che Xianping;Gu Jun;Chen Hualei;Hu Xinming;Zhou Shiying(Department of Urology,the Second Affiliated Hospital of Hainan Medical College,Haikou 570311,China)

机构地区：[1]海南医学院第二附属医院泌尿外科一区

出　　处：《疑难病杂志》2020年第2期165-169,共5页Chinese Journal of Difficult and Complicated Cases

基　　金：海南省医药卫生科研项目(1421320.27A1004)~~

摘　　要：目的观察阿托伐他汀联合雄激素阻断治疗对晚期前列腺癌患者血清前列腺特异性抗原(PSA)、血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)及血脂水平的影响。方法选取2016年1-12月海南医学院第二附属医院泌尿外科一区治疗晚期前列腺癌患者60例,均先行经尿道前列腺电切术(TURP),根据随机数字表法分为2组,每组30例。对照组术后以间断雄激素阻断治疗,观察组以阿托伐他汀联合间断雄激素阻断治疗。比较2组治疗前后血清PSA、VEGF、MMP-9、血脂水平。并随访3年,观察2组患者生存率及不良反应发生率。结果治疗后,观察组患者PSA、VEGF和MMP-9水平低于对照组(t/P=8.328/0.000、2.531/0.014、9.680/0.000);TG、TC、LDLC和HDL-C明显优于对照组(t/P=5.350/0.000、9.348/0.000、21.601/0.000、2.402/0.000)胃肠道反应、性欲减退、肝功能异常、勃起障碍及骨质疏松症等不良反应发生情况与对照组患者比较,差异无统计学意义(P>0.05);1、2、3年生存率和不良反应发生率优于对照组(χ^2/P=4.286/0.038、4.812/0.028、4.800/0.028、4.800/0.028、4.800/0.028、4.893/0.032)。结论阿托伐他汀联合雄激素阻断治疗方案可以有效降低晚期前列腺癌患者血清PSA、VEGF和MMP-9水平,改善血脂水平,提高生存率,安全性较好。Objective To observe the effects of atorvastatin combined with androgen blockade on serum prostate specific antigen(PSA),vascular endothelial growth factor(VEGF),matrix metalloproteinase 9(MMP-9)and blood lipid levels in patients with advanced prostate cancer.Methods Sixty patients with advanced prostate cancer were selected from the first urology department of the Second Affiliated Hospital of Hainan Medical College from January to December 2016.All patients underwent transurethral resection of the prostate(TURP)and were divided into 2 groups according to the random number table method,with 30 cases in each group.The control group received intermittent androgen blockade after surgery.The observation group was treated with atorvastatin combined with intermittent androgen blockade.The serum PSA,VEGF,MMP-9,and blood lipid levels were compared between the two groups before and after treatment.The patients were followed up for 3 years,and the survival rate and incidence of adverse reactions in the two groups were observed.Results After treatment,the levels of PSA,VEGF and MMP-9 in the observation group were lower than those in the control group(t/P=8.328/0.000,t/P=2.531/0.014,t/P=9.680/0.000).TG,TC,LDL-C and HDL-C were significantly better than the control group(t/P=5.350/0.000,t/P=9.348/0.000,t/P=21.601/0.000,t/P=2.402/0.000).Gastrointestinal reactions,hyposexuality,liver dysfunction,erectile dysfunction and osteoporosis were compared with those in the control group with no significant difference(P>0.05).The 1,2 and 3 year survival rate and incidence of adverse reactions were better than those of the control group(χ^2/P=4.286/0.038,χ^2/P=4.812/0.028,χ^2/P=4.800/0.028,χ^2/P=4.800/0.028,χ^2/P=4.800/0.028,χ^2/P=4.893/0.032).Conclusions Atorvastatin combined with androgen blockade can effectively reduce the serum PSA,VEGF and MMP-9 levels in patients with advanced prostate cancer,improve blood lipid levels,improve survival rate,and have better safety.

关 键 词：前列腺癌 晚期 阿托伐他汀 雄激素阻断治疗 血脂 前列腺特异性抗原 血管内皮生长因子 基质金属蛋白酶-9 

分 类 号：R737.25[医药卫生—肿瘤]